Inmune Bio, Inc. (INMB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.44+7.49%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · INMB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 167.0% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers
INMB — officer change
Dated 2026-06-17
The excerpt is incomplete and does not provide sufficient information to determine the nature of the event.
Why it matters: Progress on this partnership could drive growth and validate the company's strategy.
Supportive ifA press release will share new updates or milestones in the partnership.
Worry ifNo updates or negative news regarding the partnership in the next quarter.
Why it matters: The presentation will show data on how well XPro1595 works. Good results may help investors feel more confident.
Watch forThe company shares good results from the AAIC 2026 presentation. This shows strong data on effectiveness.
Also watch forThe company shows poor results or does not meet expectations at AAIC 2026.
Why it matters: Knowing cash burn will show the company's financial health. It will show if they can fund projects.
Watch forCash burn reported below $4.6 million in Q2.
Also watch forCash burn reported above $4.6 million in Q2.
Why it matters: If peers like Lilly or AbbVie show strong performance, it could impact Inmune Bio's outlook.
Watch forLilly or AbbVie post quarterly results showing revenue growth above 10%.
Also watch forLilly or AbbVie report revenue declines or weak guidance.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$292 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $686 loss on $10,000 · 6.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,978 loss on $10,000 · 49.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: If health care revenue grows faster again, it may mean a change for Inmune Bio.
Supportive ifHealth care revenue growth goes back to 10% or more.
Worry ifHealth care revenue growth continues to decelerate below 10%.
Why it matters: The rebates help the company's cash flow. This can support ongoing work and development.
Supportive ifThe company reports more cash runway because R&D rebates are higher than cash burn.
Worry ifThe company reports cash burn exceeding the benefits from R&D rebates.
Why it matters: Good results would show the treatment works for early Alzheimer's disease. This could help future approvals.
Supportive ifThe Phase 2b/3 trial shows clear treatment effects on thinking skills.
Worry ifThe trial fails to demonstrate significant treatment effects.
Why it matters: Good feedback on the pediatric plan could help CORDStrom get approved faster. It may also increase its market.
Supportive ifThe MHRA gives positive feedback on the pediatric plan for CORDStrom.
Worry ifThe MHRA has concerns about the pediatric plan.
Why it matters: The results may show XPro1595 works well. This could help its approval process.
Supportive ifThe company presents positive results from the MINDFuL trial at AAIC 2026.
Worry ifThe company shows poor or unclear results from the MINDFuL trial.
Why it matters: A successful change could help how money is used and boost investor trust.
Supportive ifAn announcement will confirm the successful change of the April 2024 Warrants.
Worry ifFailure to amend the warrants or negative feedback from investors.
Why it matters: This submission is an important step for getting approval for CORDStrom. If successful, it could make investors more confident.
Supportive ifThe UK MHRA will send the Marketing Authorization Application for CORDStrom by the end of 2026.
Worry ifThe company delays the MAA submission beyond 2026.
Why it matters: Starting this trial is crucial for advancing XPro1595 in early Alzheimer's disease. It could validate the treatment's potential.
Supportive ifThe Phase 2b/3 trial for XPro1595 begins as planned in late 2026.
Worry ifThe trial may start later or may not happen at all.